X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Recognizing National Glaucoma Awareness Month

By Matthew Norawong  |    February 1, 2023
January was National Glaucoma Awareness Month and provided us an opportunity to spread the word and honor the millions of patients around the world who are impacted by this debilitating disease.   ...   Read More

New Report: More than 160 medicines in development for mental illness

By Matthew Norawong  |    January 26, 2023
Mental illness represents a broad spectrum of health conditions affecting mood, thinking and behavior. These conditions include depression, bipolar disorder, schizophrenia, substance use disorder,...   Read More

ICYMI: Cancer death rate continues to decline due to treatment advances

By Matthew Norawong  |    January 25, 2023
Earlier this month, the American Cancer Society (ACS) released its annual report, Cancer Statistics 2023, finding the overall cancer mortality rate has declined 33% since peaking in 1991, leading to...   Read More

Stories from the lab: Researchers discuss innovative treatments for cancers of the blood

By Matthew Norawong  |    December 1, 2022
The biopharmaceutical industry is one of the most research-intensive of all sectors in the U.S. economy and supports a broad range of STEM jobs through R&D and manufacturing. At the backbone of the...   Read More

New Report: Nearly 800 medicines in development to treat chronic conditions

By Matthew Norawong  |    September 29, 2022
Chronic conditions impose a substantial health and economic burden that affects millions of patients, families and communities across the United States each day. While these conditions come with...   Read More

Recognizing National Sickle Cell Awareness Month

By Anne McDonald Pritchett, PhD  |    September 23, 2022
September is National Sickle Cell Awareness Month and a time for us to underscore the biopharmaceutical industry’s ongoing commitment to improve the lives of patients, families and communities...   Read More

Potential gene therapies bring hope to patients with sickle cell disease

By Katie Koziara  |    June 6, 2022
A recent analysis highlights how potential gene therapies have the potential to dramatically reduce income disparities for patients with sickle cell disease, leading to as much as $21,000 more in...   Read More

Gene therapies can reduce treatment burden and costs for patients with blood disorders

By Katie Koziara  |    May 18, 2022
A new analysis found potential gene therapies for blood disorders like hemophilia, beta thalassemia, and sickle cell disease hold promise in dramatically reducing existing treatment burdens for...   Read More

Report: More than 500 medicines in development to treat disorders of the blood

By Andrew Powaleny  |    May 18, 2022
Today, PhRMA released a new report covering 549 medicines in development to potentially treat disorders of the blood, including blood cancers. These conditions pose a significant and ongoing unmet...   Read More

Report: More than 600 medicines in development for diseases affecting women

By Lori Reilly  |    March 31, 2022
As we approach the end of celebrating Women’s History Month, we’re taking a closer look at the biopharmaceutical progress made and challenges to be addressed for women’s health.   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates